Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-01-23

Clinical Trial Update: A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML) [Phase 2]

View source ↗

Summary

A Phase 2 trial of venetoclax (ABT-199) in patients with acute myeloid leukemia has completed enrollment with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Venetoclax (venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Acute Myelogenous Leukemia, AML | Phase 2 | Status: COMPLETED | Results posted: 2018-01-23